Prevents pregnancy. ANDA 76238, held by Barr. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 76238 (Balziva-28), held by Barr, was first approved by FDA on Apr 22, 2004, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Balziva-280.035MG;0.4MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone | Rx |
| Apr 29, 2022 | Supplement 25Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 20Labeling · Standard review | Approved | None posted |
| Apr 22, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters